• Clinical look at management of pregnancy at risk of developing preeclampsia 
To content

Clinical look at management of pregnancy at risk of developing preeclampsia 

HEALTH OF WOMAN. 2015.6(102):100–104 

Clinical look at management of pregnancy at risk of developing preeclampsia 

Veropotvelyan Р. N., Solomkina A. Y., Veropotvelyan N. Р., Troyan N. Y.

«Inter-provincial center of medical genetics and prenatal diagnosis», Krivoy Rog

Kryvyi Rih city clinical hospital № 2 

A review of the literature of the early development of pre-eclampsia before 34 weeks with severe and adverse outcomes for both mother and fetus is made.

Main conceptions of pathogenesis are given as well as summarized data of systematic reviews of literature in recent years. In accordance with this it is particularlay important to develop a predictive, preventive and personalized system for pregnant women of the group with high risk of preeclampsia. 

Key words: preeclampsia, prognosis, biomarkers, prevention. 


1. World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Geneva. 2011.

2. Anderson UD, Olsson MG, Kristensen KH, Вkerstmm B, Hansson SR. 2012. Review: Biochemical markers to predict preeclampsia. Placenta 33:42–47. http://dx.doi.org/10.1016/j.placenta.2011.11.021; PMid:22197626

3. Young ВC, Levine RJ, Karumanchi SA. 2010. Pathogenesis of preeclampsia. Annu Rev Pathol. 5:173–192. http://dx.doi.org/10.1146/annurev-pathol-121808-102149; PMid:20078220

4. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. 2010. Preeclampsia. Lancet 376;9741:631–644. http://dx.doi.org/10.1016/S0140-6736(10)60279-6

5. Karumanchi SA, Lindheimer MD. 2008. Advances in the understanding of eclampsia. Curr Hypertens Rep. 10;4:305–312.

6. Liu S, Joseph KS, Liston RM, Bartholomew S, Walker M, Leon JA, Kirby RS, Sauve R, Kramer MS. 2011. Maternal Health Study Group of Canadian Perinatal Surveillance System (Public Health Agency of Canada). Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol. 118;5:987–994.

7. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M. 2011. Preeclampsia: pathophysiology, diagnosis and management. Vascular health and risk management 7:467–474.

8. Стародубов ВИ, Суханова ЛП. 2012. Репродуктивные проблемы демографического развития России. М, ИД Менеджер здравоохранения.

9. Сидорова ИС, Никитина НА. 2014. Предиктивный, превентивный подход к ведению беременных группы риска развития преэклампсии. Рос. вестник акуш.-гинек. 14;5:44–49.

10. Roberts JM, Hubel CA. 2009. The two stage model of preeclampsia: variations on the theme. Placenta 30:32–37. http://dx.doi.org/10.1016/j.placenta.2008.11.009; PMid:19070896 PMCid:PMC2680383

11. Lazdam M, Davis EF, Lewandow-ski AJ, Worton SA, Kenworthy Y, Kelly B, Leeson P. 2012. Prevention of vascular dysfunction after preeclampsia: a potential long-term outcome measure and an emerging goal for treatment. J Pregnancy 2012:704146. Published online Dec 8, 2011. http://dx.doi.org/10.1155/2012/704146

12. Evans CS, Gooch L, Flotta D, Lykins D, Powers RW, Landsittel D et al. 2011. Cardiovascular system during the postpartum state in women with a history of preeclampsia. Hypertension 58(1):57–62. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173278; PMid:21606389 PMCid:PMC3139979

13. Преэклампсия: Руководство. Под ред. ГТ Сухих, ЛЕ Мурашко. М, ГЭОТАР-Медиа. 2010.

14. Dekker G, Robillard PY, Roberts C. 2011. The etiology of preeclampsia: the role of the father. J Reprod Immunol. 89;2:126–132. http://dx.doi.org/10.1016/j.jri.2010.12.010; PMid:21529966

15. Redman CW, Sargent IL. 2010. Immunology of pre-eclampsia. Am J Reprod Immunol. 63;6:534–543.

16. Grill S, Rusterholz C, Zanetti-Dдllenbach R et al. 2009. Potential markers of preeclampsia – a review. J Reprod Biol Endocrinol. 7:70.

17. Веропотвелян ПН, Веропотвелян НП, Смородская ЕП. 2013. Современные подходы к диагностике преэклампсии. Здоровье женщины 8(84):79–84.

18. Odibo AO, Zhong Y, Longtine M, Tuuli M, Odibo L, Cahill AG, Macones GA, Nelson DM. 2011. First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction. Placenta 32;4:333–338. http://dx.doi.org/10.1016/j.placenta.2011.01.016; PMid:21324404 PMCid:PMC3673030

19. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. 2011. Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption. Eur J Obstet Gynecol Reprod Biol. 157;1:48–52. http://dx.doi.org/10.1016/j.ejogrb.2011.03.004; PMid:21482016

20. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. 2009. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet Gynecol. 33;1:23–33. http://dx.doi.org/10.1002/uog.6280; PMid:19090499

21. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo A. 2010. Predicting the risk of pre-eclampsia between 11 and 13 weeks gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat Diagn. 30;(12–13):1138–1142.

22. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. 2003. Glomerular – specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 111;5:707–716. http://dx.doi.org/10.1172/JCI17423; PMid:12618525 PMCid:PMC151905

23. Anderson UD, Olsson MG, Rutardottir S, Centlow M, Kristensen KH, Isberg PE, Thiiaganathan B, Akerstmm B, Hansson SR. 2011. Fetal hemoglobin and a1-microglobulin as first – and early second-trimester predictive biomarkers for preeclampsia. Am J Obstet Gynec. 204;6:520.el-5.

24. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA. 2013. SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm preeclampsia in nulliparous women: a predictive test accuracy study. BJOG 120;10:1215–1223.

25. Thadhani R, Mutter WP, Wolf M et al. 2004. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 89:770–775. http://dx.doi.org/10.1210/jc.2003-031244; PMid:14764795

26. Chaiworapongsa T, Romero R, Kim YM et al. 2005. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17:3-18. http://dx.doi.org/10.1080/14767050400028816; PMid:15804781

27. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. 2003. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111;5:707–716. http://dx.doi.org/10.1172/JCI17423; PMid:12618525 PMCid:PMC151905

28. Wathen KA, Tuutti E, Stenmun UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. 2006. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metabol. 91;1:180–184. http://dx.doi.org/10.1210/jc.2005-1076; PMid:16263826

29. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. 2011. Prediction of early, intermediate and late pre-eclampsia from ma temal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn. 31;1:66–74. http://dx.doi.org/10.1002/pd.2660; PMid:21210481

30. Olsson MG, Olofsson T, Tapper H, Akerstrom B. 2008. The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. Free Radie Res. 42;8:725–736. http://dx.doi.org/10.1080/10715760802337265; PMid:18712632

31. Verlohren S, Galindo A, Schlem-bach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. 2010. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 202;2;161.el-161.ell. http://dx.doi.org/10.1080/00016340802253759; PMid:18607829

32. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado E, Anna R. 2008. Endoglin, P1GF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynec Scand. 87;8:837–842.

33. Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA. 2008. D’Amore P.A. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med. 205;2:491–501.

34. Brosens I, Pijnenborg R, Vercruysse L, Romero R. 2011. The «Great Obstetrical Syndromes» are associated with disorders of deep placentation. Am J Obstet Gynec. 204;3:193–201. http://dx.doi.org/10.1016/j.ajog.2010.08.009; PMid:21094932 PMCid:PMC3369813

35. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. 2010. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG 117;11:1384–1389. http://dx.doi.org/10.1111/j.1471-0528.2010.02690.x; PMid:20840693

36. Audibert E, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. 2010. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynec. 203;4:383.el-8.

37. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, Nelson DM. 2011. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of preeclampsia. Placenta 32;8:598–602. http://dx.doi.org/10.1016/j.placenta.2011.05.006; PMid:21652068 PMCid:PMC3142303

38. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, Zwinderman AH, Robson SC, Bindels PJ, Kleijnen J, Khan KS. 2008. Use of uterine artery Doppler ultrasonogra phy to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 178;6:701–711. http://dx.doi.org/10.1503/cmaj.070430; PMid:18332385 PMCid:PMC2263112

39. Pilalis A, Souka AP, Antsaklis P, Basayiannis K, Benardis P, Haidopoulos D, Papantoniou N, Mesogitis S, Antsaklis A. 2007. Screening for preeclampsia and small for gestational age fetuses at the 11–14 weeks scan by uterine artery Dopplers. Acta Obstet Gynec Scand. 86;5:530–534. http://dx.doi.org/10.1080/00016340601155056; PMid:17464579

40. Afrakhteh М, Moeini A, Taheri MS, Haghighatkhah HR, Fakhri M, Masoom N. 2014. Uterine Doppler velocimetry of the uterine arteries in the second and third trimesters for the prediction of gestational outcome. Rev Bras Ginec Obstet. 36;1:35–39.